Comparison of HBeAg clearance rates between tenofovir alafenamide and entecavir in treatment-naive HBeAg positive chronic hepatitis B patients over 48 to 96 weeks: A retrospective cohort study
Digestive Diseases · 2026
DOI: 10.1159/000550770 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Digestive Diseases, 2026. Verfasst von Yuliang Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Tenofovir, Hepatitis B e Antigens, Guanine.
Abstract (Originalsprache)
Objectives
This retrospective cohort study aimed to compare HBeAg clearance rates at 48 and 96 weeks in treatment-naïve, HBeAg-positive CHB patients receiving TAF versus ETV therapy Patients and Methods: Of 425 initially screened HBeAg-positive CHB patients, 251 were included in the 48-week analysis (ETV: 119; TAF: 132) and 101 in the 96-week analysis (ETV: 41; TAF: 60).PSM was used to balance baseline characteristics. Multivariate cox regression identified factors associated with HBeAg clearance.
Results
At 48 weeks, a 1:1 PSM created balanced groups of 77 patients each for the 48-week comparison. the HBeAg clearance rate was significantly higher in the TAF group than in the ETV group: 22.1% versus 6.5% (χ²= 7.636, p= 0.006). The TAF group had significantly lower levels than the ETV group: (ETV: 7.94 (0.85~179.66) vs. TAF: 4.60 (0.20~70.51); p= 0.025). The reduction in HBeAg was also greater in the TAF group: (ETV: -82.10 (-189.65, -5.99) vs. TAF: -149.77 (-267.46, -15.17); p= 0.041). At week 96, 1:2 PSM yielded 66 matched patients (ETV: 24, TAF: 42). The HBeAg clearance rate was significantly higher in the TAF group (13/42, 31.0%) than in the ETV group (2/24, 8.3%) (χ²= 4.450, p = 0.035). qHBeAg levels were significantly lower in the TAF group (2.85 (0.33~33.38)) than in the ETV group (57.35 (4.78~257.45)) (p=0.001). The TAF group also showed a greater magnitude of reduction from baseline: (ETV: -81.66 (-170.58~ -1.13) vs. TAF: -260.66 (-398.15 ~ -50.31), p< 0.001). Multivariate cox analysis identified TAF treatment, baseline anti-HBe positivity , and lower baseline qHBeAg as independent predictors of HBeAg clearance.
Conclusions
For HBeAg-positive CHB patients, TAF demonstrated superior efficacy to ETV in achieving HBeAg clearance over 48-96 weeks. This effect was more pronounced in patients with lower baseline qHBeAg levels or already existing anti-HBe positivity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
- Department of Nephrology, 3201 Hospital, Hanzhong, China.
- Department of Infectious Diseases, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China, geshanfei2010@163.com.
Zitieren
APA
Zhang, Y., Wan, X., Ma, S., Wang, L., Liu, Q., Tang, Y., Malhi, L. R., & Ge, S. (2026). Comparison of HBeAg clearance rates between tenofovir alafenamide and entecavir in treatment-naive HBeAg positive chronic hepatitis B patients over 48 to 96 weeks: A retrospective cohort study. Digestive Diseases. https://doi.org/10.1159/000550770
Vancouver
Zhang Y, Wan X, Ma S, Wang L, Liu Q, Tang Y, et al. Comparison of HBeAg clearance rates between tenofovir alafenamide and entecavir in treatment-naive HBeAg positive chronic hepatitis B patients over 48 to 96 weeks: A retrospective cohort study. Digestive Diseases. 2026. doi:10.1159/000550770
BibTeX
@article{Zhang2026,
author = {Zhang, Yuliang and Wan, Xin and Ma, Shipeng and Wang, Liang and Liu, Qian and Tang, Yulun and Malhi, Lajpat Rai and Ge, Shanfei},
title = {Comparison of HBeAg clearance rates between tenofovir alafenamide and entecavir in treatment-naive HBeAg positive chronic hepatitis B patients over 48 to 96 weeks: A retrospective cohort study},
journal = {Digestive Diseases},
year = {2026},
doi = {10.1159/000550770}
}
EUVIMED